Cevidoplenib
CAS: 1703788-21-9
Ref. 3D-DTC78821
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar |
Información del producto
Cevidoplenib is a small molecule inhibitor of the receptor tyrosine kinase RET, which is associated with a variety of cancers. It binds to the active site of RET, preventing activation and causing RET to be degraded. Cevidoplenib inhibits the phosphorylation of tyrosine residues on RET, thereby blocking RET-mediated signaling cascades. This inhibition leads to decreased cell proliferation and survival in vitro and in vivo. Cevidoplenib is currently in phase II clinical trials for patients with thyroid cancer or medullary thyroid carcinoma.
Propiedades químicas
Consulta técnica sobre: 3D-DTC78821 Cevidoplenib
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
